The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic

🌐 Bloomberg (IS) —

AI Summary

Amgen’s effort to develop a potential obesity treatment began with genetic research at the University of Iceland Science Park in Reykjavík. The work forms part of the company’s push to compete in the high-stakes market for drugs associated with the success of Ozempic.

Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)

Markets Health Amgen obesity drug drug development genetics University of Iceland Science Park Reykjavík

Read original source →